Omniscient Neurotechnology
Latest round
- Series D
Last raised
- May 2026
Total raised
- $51M
Investors
- 2
About Omniscient Neurotechnology
Based in Australia, Omniscient Neurotechnology specializes in advanced neurotechnology solutions, focusing on connectomics to enhance understanding of brain connectivity for improved neurological care. Omniscient Neurotechnology, founded in 2019 in Haymarket, Australia, provides innovative neurotechnology solutions. The investment will support the commercialization of their Quicktome platform and expansion of their data science team. Stephen Scheeler serves as CEO, while the company was co-founded by Michael Sughrue, Stephane Doyen, and Stephen Scheeler. The company has completed 6 deals to date, with the most recent deal occurring on 01/06/2026. Omniscient Neurotechnology specializes in advanced neurotechnology solutions, focusing on connectomics—the study of brain connectivity. Their core product, Quicktome, is an AI-powered connectomic analysis platform that processes vast amounts of neural data to produce individualized insights into a patient's unique brain networks and functions. This platform aids clinicians in creating personalized treatment roadmaps for various neurological conditions such as depression, Alzheimer's disease, and stroke. Omniscient serves a diverse clientele that includes neurosurgeons, psychologists, and researchers, primarily in North America, Europe, and parts of Asia. The company's solutions are designed to enhance surgical planning and patient outcomes by providing actionable intelligence prior to critical surgeries. Omniscient Neurotechnology generates revenue through a business-to-business model, primarily engaging with healthcare institutions and professionals who utilize their flagship product, Quicktome. Transactions typically occur via subscription agreements or contractual partnerships where clients pay for access to the platform and its associated services. This structure enables institutions to integrate Quicktome into their diagnostic and treatment workflows, facilitating ongoing revenue streams for the company. The pricing model reflects the comprehensive analytics and insights provided by the platform, allowing healthcare providers to enhance patient care effectively while driving the company's financial performance. The revenue generated supports continued research and development efforts in the field of brain health and analytics.
Who invested in Omniscient Neurotechnology
2 investors across 2 rounds
See all investors in Omniscient Neurotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Omniscient Neurotechnology
Who invested in Omniscient Neurotechnology?
Omniscient Neurotechnology has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Omniscient Neurotechnology raised?
Omniscient Neurotechnology has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Omniscient Neurotechnology last raise money?
Omniscient Neurotechnology's most recent round on record is a Series D, in May 2026.
What does Omniscient Neurotechnology do?
Based in Australia, Omniscient Neurotechnology specializes in advanced neurotechnology solutions, focusing on connectomics to enhance understanding of brain connectivity for improved neurological care.
Where is Omniscient Neurotechnology headquartered?
Omniscient Neurotechnology is headquartered in Sydney, Australia.
Which VCs invest in companies like Omniscient Neurotechnology?
Among active investors with capital left to deploy, Blackbird, AirTree Ventures, Square Peg and Immutable Ventures back medical devices & equipment companies at Omniscient Neurotechnology's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series D
Raising like Omniscient Neurotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.